Belite Bio (BLTE) Share-based Compensation (2022 - 2025)

Belite Bio's Share-based Compensation history runs 4 years deep, the most recent figure standing at $11.7 million for Q4 2025.

• On a quarterly basis, Share-based Compensation rose 366.59% year-over-year to $11.7 million in Q4 2025; TTM through Dec 2023 was $3.4 million, a 571.79% increase from a year earlier, with the FY2025 full-year figure at $38.9 million, up 1377.56% from the prior year.
• Share-based Compensation grew to $11.7 million in Q4 2025 per BLTE's latest filing, from -$4.4 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $11.7 million in Q4 2025 and bottomed at -$4.4 million in Q4 2024.
• The 4-year median for Share-based Compensation is $2.0 million (2022), against an average of $2.8 million.
• Across the five-year window, Share-based Compensation surged 571.79% in 2023 and sank 229.01% in 2024, its largest moves.
• Year by year, Share-based Compensation stood at $507000.0 in 2022, then jumped by 571.79% to $3.4 million in 2023, then sank by 229.01% to -$4.4 million in 2024, then jumped by 366.59% to $11.7 million in 2025.
• Per Business Quant, the three latest BLTE Share-based Compensation figures stand at $11.7 million (Q4 2025), -$4.4 million (Q4 2024), and $3.4 million (Q4 2023).